Scholar Rock Holding Corporation (SRRK): Price and Financial Metrics
GET POWR RATINGS... FREE!
SRRK POWR Grades
- Growth is the dimension where SRRK ranks best; there it ranks ahead of 55.1% of US stocks.
- SRRK's strongest trending metric is Momentum; it's been moving down over the last 179 days.
- SRRK's current lowest rank is in the Momentum metric (where it is better than 14.48% of US stocks).
SRRK Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for SRRK is 0.11 -- better than merely 11.91% of US stocks.
- Of note is the ratio of Scholar Rock Holding Corp's sales and general administrative expense to its total operating expenses; merely 12.05% of US stocks have a lower such ratio.
- With a price/sales ratio of 25.72, Scholar Rock Holding Corp has a higher such ratio than 94.03% of stocks in our set.
- Stocks that are quantitatively similar to SRRK, based on their financial statements, market capitalization, and price volatility, are CCCC, NTLA, ORMP, MTEM, and FDMT.
- SRRK's SEC filings can be seen here. And to visit Scholar Rock Holding Corp's official web site, go to scholarrock.com.
SRRK Valuation Summary
- SRRK's price/earnings ratio is -12.6; this is 134.52% lower than that of the median Healthcare stock.
- Over the past 40 months, SRRK's price/sales ratio has gone NA NA.
- SRRK's EV/EBIT ratio has moved up 1.1 over the prior 40 months.
Below are key valuation metrics over time for SRRK.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
SRRK | 2021-08-31 | 86.3 | 6.3 | -12.6 | -11.1 |
SRRK | 2021-08-30 | 84.0 | 6.1 | -12.2 | -10.8 |
SRRK | 2021-08-27 | 87.7 | 6.4 | -12.7 | -11.3 |
SRRK | 2021-08-26 | 85.5 | 6.2 | -12.4 | -11.0 |
SRRK | 2021-08-25 | 86.4 | 6.3 | -12.6 | -11.1 |
SRRK | 2021-08-24 | 87.0 | 6.3 | -12.6 | -11.2 |
SRRK's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SRRK has a Quality Grade of D, ranking ahead of 18.4% of graded US stocks.
- SRRK's asset turnover comes in at 0.051 -- ranking 322nd of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows SRRK's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.051 | 1 | -0.678 |
2021-03-31 | 0.056 | 1 | -0.719 |
2020-12-31 | 0.070 | 1 | -0.841 |
2020-09-30 | 0.113 | 1 | -0.949 |
2020-06-30 | 0.119 | 1 | -0.788 |
2020-03-31 | 0.118 | 1 | -0.618 |
SRRK Price Target
For more insight on analysts targets of SRRK, see our SRRK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $64.67 | Average Broker Recommendation | 1.3 (Strong Buy) |
SRRK Stock Price Chart Interactive Chart >
SRRK Price/Volume Stats
Current price | $5.05 | 52-week high | $44.95 |
Prev. close | $5.18 | 52-week low | $4.84 |
Day low | $4.84 | Volume | 489,600 |
Day high | $5.16 | Avg. volume | 383,311 |
50-day MA | $9.64 | Dividend yield | N/A |
200-day MA | $22.62 | Market Cap | 178.28M |
Scholar Rock Holding Corporation (SRRK) Company Bio
Scholar Rock Holding Corporation discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was founded in 2012 and is based in Cambridge, Massachusetts.
Latest SRRK News From Around the Web
Below are the latest news stories about Scholar Rock Holding Corp that investors may wish to consider to help them evaluate SRRK as an investment opportunity.
Scholar Rock to Present at Cowen’s 42nd Annual Health Care ConferenceCAMBRIDGE, Mass., February 25, 2022--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in an Orphan Neuro and Neuromuscular panel discussion at Cowen’s 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:10 a.m. ET. |
The past year for Scholar Rock Holding (NASDAQ:SRRK) investors has not been profitableAs every investor would know, you don't hit a homerun every time you swing. But serious investors should think long and... |
Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGFβ for Immuno-Oncology Drug Development SummitCAMBRIDGE, Mass., January 25, 2022--Scholar Rock today announced a presentation at the 2nd Annual TGFβ for Immuno-Oncology Drug Development Summit (January 25-27, 2022). |
Scholar Rock (SRRK) Presents At 40th Annual J.P. Morgan Virtual Healthcare ConferenceNo summary available. |
Scholar Rock Provides Corporate Update and Highlights Priorities for 2022CAMBRIDGE, Mass., January 10, 2022--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2022. |
SRRK Price Returns
1-mo | -43.13% |
3-mo | -68.87% |
6-mo | N/A |
1-year | -81.13% |
3-year | -74.01% |
5-year | N/A |
YTD | -79.67% |
2021 | -48.82% |
2020 | 268.21% |
2019 | -42.62% |
2018 | N/A |
2017 | N/A |
Continue Researching SRRK
Here are a few links from around the web to help you further your research on Scholar Rock Holding Corp's stock as an investment opportunity:Scholar Rock Holding Corp (SRRK) Stock Price | Nasdaq
Scholar Rock Holding Corp (SRRK) Stock Quote, History and News - Yahoo Finance
Scholar Rock Holding Corp (SRRK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...